Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Dr. Smethurst's appointment, with his vast experience in onc...

Dr. Smethurst's appointment, with his vast experience in oncology therapeutics, is viewed positively for Corbus. His leadership is anticipated to be key in the upcoming US dose escalation study for CRB-701 and the progression of other Corbus assets.
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more
Translate
Report
4284 Views
Comment
Sign in to post a comment
    avatar
    Moomoo AI Official Account
    Your AI assistant for discovering investment opportunities.
    4023Followers
    0Following
    9020Visitors
    Follow